European Association of Nuclear Medicine (EANM)’s Post

Important for discovery and development of new targeting therapies.

“Equity in health is non-negotiable” - Commissioner Stella Kyriakides “The final destination is a Europe without cancer” - European Parliament President Roberta Metsola A few days before the #WorldCancerDay, the European Commission held the "Europe's Beating Cancer Plan: Joining Forces" conference. Marked by impactful messages and compelling patient testimonials, the event underscored critical themes such as "prevention" and "accessibility." These pivotal aspects align with Nuclear Medicine Europe's resolute advocacy for enhanced patient access and early diagnosis. A crucial step forward involves harmonizing the legislative framework across Europe to ensure comprehensive improvement. #EUCancerPlan #WorldCancerDay #HealthUnion #radiopharmaceuticals #nuclearmedicine

Interesting article

The Swiss Business Hub Japan is excited to share a milestone video from Drugs for Neglected Diseases initiative - DNDi, a non-profit organization making waves in the pharmaceutical research sector. Headquartered in Geneva with a pivotal office right here in Tokyo, DNDi is dedicated to changing the narrative for the world’s most vulnerable populations. 🔗 Watch here: https://lnkd.in/gGYUscrt Celebrating 20 years of groundbreaking work, DNDi's latest documentary, "Out of the Shadows," shines a light on the often-overlooked crises of neglected diseases. The film features the inspiring efforts of three DNDi scientists in Brazil, the Democratic Republic of Congo, and Sri Lanka, who are at the forefront of developing life-saving treatments. This poignant film not only reflects on DNDi's journey of bringing new hope and health to millions but also underscores their ongoing commitment to harnessing advanced science and technology, including AI, to fight against neglected diseases. Now with Japanese subtitles, we hope this film resonates deeply and inspires action here in Japan and beyond. Let's support DNDi in bringing critical healthcare solutions out of the shadows and into the spotlight. #DNDi #GlobalHealth #Innovation #NeglectedDiseases #HealthcareHeroes #switzerland #japan #pharmaceuticals Spread the word and help us raise awareness about this vital cause!

It is interesting to see that various companies are working on figuring out how to #synthesize #pharmaceutical #drugs in #orbit! https://lnkd.in/gp9WMBYc

The challenges of steering a hypersonic plane >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #productmarketing #biotech

The challenges of steering a hypersonic plane >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #productmarketing #healthcare

News Alert 📣 Our Managing Director, Prof. Dr. Dirk Roggenbuck, is part of the current issue of BioSpectrum 01/2024 , in which he addresses the challenges SMEs in the diagnostics industry are facing due to increasing regulatory requirements and costs under the EU's IVDR. Prof. Dr. Roggenbuck highlights the impact on the innovation and competitiveness of SMEs, particularly in niche markets or in areas with rare diseases. The increased regulatory requirements lead to significantly higher costs for product monitoring and the commissioning of external testing bodies. To overcome these challenges, many SMEs need to explore alternative business models for sustainability. Prof. Dr. Roggenbuck's insights from his many years of experience at Medipan GmbH and GA Generic Assays GmbH offer valuable perspectives. As an honorary professor and spokesperson for innovation alliances, he emphasizes the need for collective action to find solutions and ensure the resilience of SMEs in the diagnostics industry. The IVDR undoubtedly poses a significant challenge for SMEs operating in the diagnostics industry. It is imperative that we collectively address these challenges and devise solutions to safeguard the innovation capacity and competitiveness of these businesses. For more in-depth information on this crucial topic, We encourage you to read the full article here: https://lnkd.in/dW2qmtzQ #Medipan #GAGenericAssays

A newly FDA-approved blood test, developed by the U.S. Army Medical Materiel Development Activity at Fort Detrick and Abbott can detect signs of traumatic brain injury more quickly than before. This groundbreaking device uses biomarkers discovered by Banyan Biomarkers, #OrigiGator and graduate of UF Innovate | Accelerate at Sid Martin Biotech. The i-STAT Alinity device analyzes blood samples to detect elevated levels of Banyan’s biomarkers, UCH-L1 and GFAP, indicating brain bleeds or injuries. If the biomarkers are detected, patients can be swiftly transported for further diagnosis and treatment. USAMMDA leads medical product development for the U.S. Army, while Abbott Point of Care, a division of Abbott Laboratories, collaborated on this project. The partnership with Banyan Biomarkers signifies a major advancement, as Abbott received licensure from Banyan in 2019 to integrate the company's biomarkers into the i-STAT Alinity device. Read more at: https://lnkd.in/eGeMEvDD

Watch the Locsense Artemis ST in action. Learn about the ease of use and key benefits for drug development and toxicology research. #Locsense #CellResearch #ScienceInnovation #3R #drugdiscovery #cellbiology #lifesciences